Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Approves Return of Popular Primatene Mist Asthma Inhaler

By Linda A. Johnson, AP Medical Writer | November 8, 2018

This undated product image provided by Amphastar shows Primatene Mist. A new version of the once-popular asthma inhaler Primatene Mist will soon return to U.S. stores. The Food and Drug Administration on Wednesday, Nov. 7, 2018, approved its over-the-counter aerosol inhaler for ages 12 and up. (Amphastar via AP)

A new version of the once-popular asthma inhaler Primatene Mist will soon return to U.S. stores.

The Food and Drug Administration approved the over-the-counter aerosol inhaler late Wednesday. It’s for temporary relief of mild, intermittent asthma symptoms in people ages 12 and up.

The original Primatene Mist was discontinued seven years ago because the inhaler’s ozone-depleting propellant had been banned. That version had been marketed for half a century, including in memorable TV ads.

The new product developed by Amphastar Pharmaceuticals uses a safer propellant. The inhaler will cost about $25 and contain 160 doses. It should be available by the end of the year.

“Rescue inhalers” are meant to quickly relieve asthma symptoms such as wheezing, coughing, shortness of breath and chest tightness, which can be triggered by pollen, mold, dust mites, pet dander, stress or exercising in the cold.

Primatene Mist’s active ingredient, the hormone epinephrine, relaxes muscles in the lungs to increase airflow. The product is the only FDA-approved over-the-counter inhaler. Numerous prescription rescue inhalers, containing the medicine albuterol or levalbuterol, are available.

In a statement Thursday, FDA officials noted concerns that some people may inappropriately use or overuse the new inhaler. The agency said it should not be substituted for prescription treatments or used by people with severe asthma.

Primatene Mist was pulled from stores in 2011, but it still has many fans, including tens of thousands who have liked Facebook pages advocating its return. TV ads for the old version touted its speedy relief with endorsements from athletes such as Bob Gibson and Jackie Joyner-Kersee, or by showing a gasping person getting relief as a stopwatch ticked off 15 seconds.

An Amphastar subsidiary bought rights to the product’s name and spent several years improving it.

The new version contains less alcohol and epinephrine, which can increase heart rate, especially if the inhaler is used too much. Side effects include tremors and dizziness.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE